Clinical Trial Update: DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury [Phase 2, Phase 3]

View source ↗

Summary

DIAMOND trial evaluating dual antiplatelet therapy to reduce myocardial injury in coronary artery disease, with Phase 2 and Phase 3 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Aspirin (Aspirin)
• P2Y12 inhibitor (P2Y12 receptor inhibitor)

Snippet

Sponsor: University of Edinburgh | Conditions: Coronary Artery Disease | Phase 2, Phase 3 | Status: COMPLETED